Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer have?
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer has 2,652 citations in the OpenAlex counts ScholarIQ stores.
When was Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer published?
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer has 2018 year in the ScholarIQ index.
What is the open-access status of Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer?
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer?
The DOI for Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer is on the source record.
What is the PMID of Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer?
The PMID for Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer is on the source record.
What is the OpenAlex record for Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer?
The OpenAlex for Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer is on the source record.